Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR)
| Autor: | Keunchil Park, Conrad R. Lewanski, Fadi Braiteh, A. Artal-Cortes, Alan Sandler, Achim Rittmeyer, Julien Mazieres, Jing Yi, Pei He, Johan Vansteenkiste, Wei Zou, Louis Fehrenbacher, Daniel S. Chen, Alexander I. Spira, Marcus Ballinger, Daniel Waterkamp, David J. Smith |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty business.industry Phases of clinical research 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Docetaxel Atezolizumab 030220 oncology & carcinogenesis Internal medicine medicine Biomarker (medicine) business medicine.drug |
| Zdroj: | Pneumologie. 71:S1-S125 |
| ISSN: | 1438-8790 0934-8387 |
| DOI: | 10.1055/s-0037-1598330 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|